SIGIRR
(Single Immunoglobulin and Toll-Interleukin 1 Receptor (TIR) Domain (SIGIRR))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
Attributs du produit
This is a synthetic peptide designed for use in combination with anti-SIGIRR antibody (Catalog #: ARP49664_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Concentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Conseil sur la manipulation
Avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Antigène
SIGIRR
(Single Immunoglobulin and Toll-Interleukin 1 Receptor (TIR) Domain (SIGIRR))
Synonymes
TIR8 Peptide, AI256711 Peptide, sc:d148 Peptide, RGD1306732 Peptide, single Ig and TIR domain containing Peptide, single immunoglobulin and toll-interleukin 1 receptor (TIR) domain Peptide, SIGIRR Peptide, Sigirr Peptide, sigirr Peptide
Sujet
SIGIRR acts as a negative regulator of the Toll-like and IL-1R receptor signaling pathways. It attenuates the recruitment of receptor-proximal signaling components to the TLR4 receptor, probably through a TIR-TIR domain interaction with TLR4. Through its extracellular domain it interferes with the heterodimerization of Il1R1 and IL1RAP.
Alias Symbols: MGC110992, TIR8
Protein Interaction Partner: ENO2,IL1R1,IRAK1,RPN1,SIGIRR,TLR4,TLR5,TLR9,TRAF6,ENO2,IL1R1,IRAK1,SIGIRR,TLR4,TRAF6